Mediation Analysis of Urine Osmolality and Response to Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Assessment.

Nephrology (Carlton)Oct 1, 2026
Clinical ResearchNephrology

Ryo Matsuura, Kent Doi, Zhen Zhang et al.

✦ AI-curated · Sources linked

In 30 seconds

This post hoc analysis of the TEMPO 3:4 randomized controlled trial evaluated urine osmolality (Uosm) as a biomarker for long-term response to tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD). In the non-Japanese cohort (n=948), a significant average causal mediation effect of Uosm on eGFR at month 36 was found (2.4).

Key findings

  • In the non-Japanese cohort, the average causal mediation effect of Uosm on eGFR was 2.4.
  • The average direct effect of tolvaptan on eGFR in the Japanese cohort was 8.4.
  • Tolvaptan significantly reduced TKV by -8.3% in the non-Japanese cohort.
  • Tolvaptan significantly reduced TKV by -12.0% in the Japanese cohort.

Why it matters

Understanding the role of urine osmolality as a biomarker may help clinicians predict long-term kidney function outcomes in ADPKD patients treated with tolvaptan, potentially guiding treatment decisions.

Source

PubMed · PMID 42813962

Published in Nephrology (Carlton). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.